Neurogene Stock Today
| NGNE Stock | 15.58 0.56 3.47% |
PerformanceVery Weak
| Odds Of DistressLow
|
Neurogene is trading at 15.58 as of the 27th of March 2025, a 3.47 percent decrease since the beginning of the trading day. The stock's lowest day price was 15.58. Neurogene has about a 22 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 27th of December 2024 and ending today, the 27th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of March 2014 | Category Healthcare | Classification Health Care |
Neurogene is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 14.85 M outstanding shares of which 1.75 M shares are now shorted by private and institutional investors with about 12.51 trading days to cover. More on Neurogene
Moving together with Neurogene Stock
Moving against Neurogene Stock
Neurogene Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CFO President | Christine JD | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
| Debt LevelsNeurogene can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Neurogene's financial leverage. It provides some insight into what part of Neurogene's total assets is financed by creditors.
LiquidityNeurogene currently holds 12.43 M in liabilities. Note, when we think about Neurogene's use of debt, we should always consider it together with its cash and equity.
| |||||
Neurogene (NGNE) is traded on NASDAQ Exchange in USA. It is located in 535 W 24th Street, New York, NY, United States, 10011 and employs 107 people. Neurogene is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 239.75 M. Neurogene conducts business under Biotechnology sector and is part of Health Care industry. The entity has 14.85 M outstanding shares of which 1.75 M shares are now shorted by private and institutional investors with about 12.51 trading days to cover.
Neurogene generates negative cash flow from operations
Check Neurogene Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Neurogene is USD239.75 Million. The majority of Neurogene outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Neurogene to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Neurogene. Please pay attention to any change in the institutional holdings of Neurogene as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Neurogene Ownership Details
Neurogene Historical Income Statement
Neurogene Stock Against Markets
Neurogene Corporate Management
| MD MBA | Senior Development | Profile | |
| Effie MD | Senior Research | Profile | |
| Donna JD | Senior Counsel | Profile | |
| CPI FAAP | Quality Affairs | Profile | |
| Ricardo Jimenez | Senior Operations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.